Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

PURPOSE: Determine the efficacy and safety of first-line ribociclib plus letrozole in elderly patients with HR+, HER2− advanced breast cancer. METHODS: 668 postmenopausal women with HR+, HER2− advanced breast cancer and no prior systemic therapy for advanced disease were enrolled in the Phase III MO...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Breast Cancer Res Treat
Main Authors: Sonke, Gabe S., Hart, Lowell L., Campone, Mario, Erdkamp, Frans, Janni, Wolfgang, Verma, Sunil, Villanueva, Cristian, Jakobsen, Erik, Alba, Emilio, Wist, Erik, Favret, Anne M., Bachelot, Thomas, Hegg, Roberto, Wheatley-Price, Paul, Souami, Farida, Sutradhar, Santosh, Miller, Michelle, Germa, Caroline, Burris, Howard A.
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer US 2017
נושאים:
Clinical Trial
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5807486/
https://ncbi.nlm.nih.gov/pubmed/29058175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4523-y
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים